Need immediate assistance? Call 1-518-730-0559 (Us-Canada Toll Free) or Contact Us

 

Biopharmaceutical Contract Manufacturing Market: Oncology Segment by Therapeutic Area to Dominate the Global Market Through 2027: Global Industry Analysis 2012 - 2016 and Opportunity Assessment 2017 - 2027

Table of Content

1. Executive Summary
1.1. Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune

2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition

3. Biopharmaceutical Contract Manufacturing Market View Point Analysis
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
3.3. Regulatory Scenario

4. North America Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027
4.1. Introduction
4.2. Regional Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Trends
4.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
4.3.1. U.S.
4.3.2. Canada
4.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
4.4.1. U.S.
4.4.2. Canada
4.5. Historical Market Size (US$ Mn) By Platform, 2012-2016
4.5.1. Mammalian-based
4.5.2. Microbial-based
4.6. Market Size (US$ Mn) Forecast By Platform, 2017-2027
4.6.1. Mammalian-based
4.6.2. Microbial-based
4.7. Historical Market Size (US$ Mn) By Product Type, 2012-2016
4.7.1. Monoclonal Antibodies
4.7.2. Recombinant Proteins
4.7.3. Vaccines
4.7.4. Insulin
4.7.5. Interferons
4.7.6. Growth Factors
4.7.7. Others
4.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
4.8.1. Monoclonal Antibodies
4.8.2. Recombinant Proteins
4.8.3. Vaccines
4.8.4. Insulin
4.8.5. Interferons
4.8.6. Growth Factors
4.8.7. Others
4.9. Historical Market Size (US$ Mn) By Application, 2012-2016
4.9.1. Clinical
4.9.2. Commercial
4.10. Market Size (US$ Mn) Forecast By Application, 2017-2027
4.10.1. Clinical
4.10.2. Commercial
4.11. Historical Market Size (US$ Mn) By Therapeutic Area, 2012-2016
4.11.1. Autoimmune Disease
4.11.2. Oncology
4.11.3. Metabolic Disease
4.11.4. Opthalmology
4.11.5. Cardiovascular Disease
4.11.6. Infectious Disease
4.11.7. Neurology
4.11.8. Respiratory Disorder
4.11.9. Others
4.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017-2027
4.12.1. Autoimmune Disease
4.12.2. Oncology
4.12.3. Metabolic Disease
4.12.4. Opthalmology
4.12.5. Cardiovascular Disease
4.12.6. Infectious Disease
4.12.7. Neurology
4.12.8. Respiratory Disorder
4.12.9. Others
4.13. Market Attractiveness Analysis
4.13.1. By Country
4.13.2. By Platform
4.13.3. By Product Type
4.13.4. By Application
4.13.5. By Therapeutic Area
4.14. Key Representative Market Participants
4.15. Market Presence (Intensity Map)

5. Latin America Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027
5.1. Introduction
5.2. Regional Market Dynamics
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Trends
5.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
5.3.1. Brazil
5.3.2. Mexico
5.3.3. Rest of Latin America
5.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
5.4.1. Brazil
5.4.2. Mexico
5.4.3. Rest of Latin America
5.5. Historical Market Size (US$ Mn) By Platform, 2012-2016
5.5.1. Mammalian-based
5.5.2. Microbial-based
5.6. Market Size (US$ Mn) Forecast By Platform, 2017-2027
5.6.1. Mammalian-based
5.6.2. Microbial-based
5.7. Historical Market Size (US$ Mn) By Product Type, 2012-2016
5.7.1. Monoclonal Antibodies
5.7.2. Recombinant Proteins
5.7.3. Vaccines
5.7.4. Insulin
5.7.5. Interferons
5.7.6. Growth Factors
5.7.7. Others
5.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
5.8.1. Monoclonal Antibodies
5.8.2. Recombinant Proteins
5.8.3. Vaccines
5.8.4. Insulin
5.8.5. Interferons
5.8.6. Growth Factors
5.8.7. Others
5.9. Historical Market Size (US$ Mn) By Application, 2012-2016
5.9.1. Clinical
5.9.2. Commercial
5.10. Market Size (US$ Mn) Forecast By Application, 2017-2027
5.10.1. Clinical
5.10.2. Commercial
5.11. Historical Market Size (US$ Mn) By Therapeutic Area, 2012-2016
5.11.1. Autoimmune Disease
5.11.2. Oncology
5.11.3. Metabolic Disease
5.11.4. Opthalmology
5.11.5. Cardiovascular Disease
5.11.6. Infectious Disease
5.11.7. Neurology
5.11.8. Respiratory Disorder
5.11.9. Others
5.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017-2027
5.12.1. Autoimmune Disease
5.12.2. Oncology
5.12.3. Metabolic Disease
5.12.4. Opthalmology
5.12.5. Cardiovascular Disease
5.12.6. Infectious Disease
5.12.7. Neurology
5.12.8. Respiratory Disorder
5.12.9. Others
5.13. Market Attractiveness Analysis
5.13.1. By Country
5.13.2. By Platform
5.13.3. By Product Type
5.13.4. By Application
5.13.5. By Therapeutic Area
5.14. Key Representative Market Participants
5.15. Market Presence (Intensity Map)

6. Western Europe Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027
6.1. Introduction
6.2. Regional Market Dynamics
6.2.1. Drivers
6.2.2. Restraints
6.2.3. Trends
6.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016
6.3.1. Germany
6.3.2. Italy
6.3.3. France
6.3.4. Spain
6.3.5. U.K.
6.3.6. BENELUX
6.3.7. Nordic
6.3.8. Rest of Western Europe
6.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
6.4.1. Germany
6.4.2. Italy
6.4.3. France
6.4.4. Spain
6.4.5. U.K.
6.4.6. BENELUX
6.4.7. Nordic
6.4.8. Rest of Western Europe
6.5. Historical Market Size (US$ Mn) By Platform, 2012-2016
6.5.1. Mammalian-based
6.5.2. Microbial-based
6.6. Market Size (US$ Mn) Forecast By Platform, 2017-2027
6.6.1. Mammalian-based
6.6.2. Microbial-based
6.7. Historical Market Size (US$ Mn) By Product Type, 2012-2016
6.7.1. Monoclonal Antibodies
6.7.2. Recombinant Proteins
6.7.3. Vaccines
6.7.4. Insulin
6.7.5. Interferons
6.7.6. Growth Factors
6.7.7. Others
6.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
6.8.1. Monoclonal Antibodies
6.8.2. Recombinant Proteins
6.8.3. Vaccines
6.8.4. Insulin
6.8.5. Interferons
6.8.6. Growth Factors
6.8.7. Others
6.9. Historical Market Size (US$ Mn) By Application, 2012-2016
6.9.1. Clinical
6.9.2. Commercial
6.10. Market Size (US$ Mn) Forecast By Application, 2017-2027
6.10.1. Clinical
6.10.2. Commercial
6.11. Historical Market Size (US$ Mn) By Therapeutic Area, 2012-2016
6.11.1. Autoimmune Disease
6.11.2. Oncology
6.11.3. Metabolic Disease
6.11.4. Opthalmology
6.11.5. Cardiovascular Disease
6.11.6. Infectious Disease
6.11.7. Neurology
6.11.8. Respiratory Disorder
6.11.9. Others
6.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017-2027
6.12.1. Autoimmune Disease
6.12.2. Oncology
6.12.3. Metabolic Disease
6.12.4. Opthalmology
6.12.5. Cardiovascular Disease
6.12.6. Infectious Disease
6.12.7. Neurology
6.12.8. Respiratory Disorder
6.12.9. Others
6.13. Market Attractiveness Analysis
6.13.1. By Country
6.13.2. By Platform
6.13.3. By Product Type
6.13.4. By Application
6.13.5. By Therapeutic Area
6.14. Key Representative Market Participants
6.15. Market Presence (Intensity Map)

7. Eastern Europe Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027
7.1. Introduction
7.2. Regional Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Trends
7.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
7.3.1. Russia
7.3.2. Poland
7.3.3. Rest of Eastern Europe
7.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
7.4.1. Russia
7.4.2. Poland
7.4.3. Rest of Eastern Europe
7.5. Historical Market Size (US$ Mn) By Platform, 2012-2016
7.5.1. Mammalian-based
7.5.2. Microbial-based
7.6. Market Size (US$ Mn) Forecast By Platform, 2017-2027
7.6.1. Mammalian-based
7.6.2. Microbial-based
7.7. Historical Market Size (US$ Mn) By Product Type, 2012-2016
7.7.1. Monoclonal Antibodies
7.7.2. Recombinant Proteins
7.7.3. Vaccines
7.7.4. Insulin
7.7.5. Interferons
7.7.6. Growth Factors
7.7.7. Others
7.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
7.8.1. Monoclonal Antibodies
7.8.2. Recombinant Proteins
7.8.3. Vaccines
7.8.4. Insulin
7.8.5. Interferons
7.8.6. Growth Factors
7.8.7. Others
7.9. Historical Market Size (US$ Mn) By Application, 2012-2016
7.9.1. Clinical
7.9.2. Commercial
7.10. Market Size (US$ Mn) Forecast By Application, 2017-2027
7.10.1. Clinical
7.10.2. Commercial
7.11. Historical Market Size (US$ Mn) By Therapeutic Area, 2012-2016
7.11.1. Autoimmune Disease
7.11.2. Oncology
7.11.3. Metabolic Disease
7.11.4. Opthalmology
7.11.5. Cardiovascular Disease
7.11.6. Infectious Disease
7.11.7. Neurology
7.11.8. Respiratory Disorder
7.11.9. Others
7.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017-2027
7.12.1. Autoimmune Disease
7.12.2. Oncology
7.12.3. Metabolic Disease
7.12.4. Opthalmology
7.12.5. Cardiovascular Disease
7.12.6. Infectious Disease
7.12.7. Neurology
7.12.8. Respiratory Disorder
7.12.9. Others
7.13. Market Attractiveness Analysis
7.13.1. By Country
7.13.2. By Platform
7.13.3. By Product Type
7.13.4. By Application
7.13.5. By Therapeutic Area
7.14. Key Representative Market Participants
7.15. Market Presence (Intensity Map)

8. Asia Pacific excluding Japan Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027
8.1. Introduction
8.2. Regional Market Dynamics
8.2.1. Drivers
8.2.2. Restraints
8.2.3. Trends
8.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
8.3.1. China
8.3.2. India
8.3.3. Australia and New Zealand
8.3.4. ASEAN
8.3.5. South Korea
8.3.6. Rest of APEJ
8.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
8.4.1. China
8.4.2. India
8.4.3. Australia and New Zealand
8.4.4. ASEAN
8.4.5. South Korea
8.4.6. Rest of APEJ
8.5. Historical Market Size (US$ Mn) By Platform, 2012-2016
8.5.1. Mammalian-based
8.5.2. Microbial-based
8.6. Market Size (US$ Mn) Forecast By Platform, 2017-2027
8.6.1. Mammalian-based
8.6.2. Microbial-based
8.7. Historical Market Size (US$ Mn) By Product Type, 2012-2016
8.7.1. Monoclonal Antibodies
8.7.2. Recombinant Proteins
8.7.3. Vaccines
8.7.4. Insulin
8.7.5. Interferons
8.7.6. Growth Factors
8.7.7. Others
8.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
8.8.1. Monoclonal Antibodies
8.8.2. Recombinant Proteins
8.8.3. Vaccines
8.8.4. Insulin
8.8.5. Interferons
8.8.6. Growth Factors
8.8.7. Others
8.9. Historical Market Size (US$ Mn) By Application, 2012-2016
8.9.1. Clinical
8.9.2. Commercial
8.10. Market Size (US$ Mn) Forecast By Application, 2017-2027
8.10.1. Clinical
8.10.2. Commercial
8.11. Historical Market Size (US$ Mn) By Therapeutic Area, 2012-2016
8.11.1. Autoimmune Disease
8.11.2. Oncology
8.11.3. Metabolic Disease
8.11.4. Opthalmology
8.11.5. Cardiovascular Disease
8.11.6. Infectious Disease
8.11.7. Neurology
8.11.8. Respiratory Disorder
8.11.9. Others
8.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017-2027
8.12.1. Autoimmune Disease
8.12.2. Oncology
8.12.3. Metabolic Disease
8.12.4. Opthalmology
8.12.5. Cardiovascular Disease
8.12.6. Infectious Disease
8.12.7. Neurology
8.12.8. Respiratory Disorder
8.12.9. Others
8.13. Market Attractiveness Analysis
8.13.1. By Country
8.13.2. By Platform
8.13.3. By Product Type
8.13.4. By Application
8.13.5. By Therapeutic Area
8.14. Key Representative Market Participants
8.15. Market Presence (Intensity Map)

9. Japan Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027
9.1. Introduction
9.2. Regional Market Dynamics
9.2.1. Drivers
9.2.2. Restraints
9.2.3. Trends
9.3. Historical Market Size (US$ Mn) By Platform, 2012-2016
9.3.1. Mammalian-based
9.3.2. Microbial-based
9.4. Market Size (US$ Mn) Forecast By Platform, 2017-2027
9.4.1. Mammalian-based
9.4.2. Microbial-based
9.5. Historical Market Size (US$ Mn) By Product Type, 2012-2016
9.5.1. Monoclonal Antibodies
9.5.2. Recombinant Proteins
9.5.3. Vaccines
9.5.4. Insulin
9.5.5. Interferons
9.5.6. Growth Factors
9.5.7. Others
9.6. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
9.6.1. Monoclonal Antibodies
9.6.2. Recombinant Proteins
9.6.3. Vaccines
9.6.4. Insulin
9.6.5. Interferons
9.6.6. Growth Factors
9.6.7. Others
9.7. Historical Market Size (US$ Mn) By Application, 2012-2016
9.7.1. Clinical
9.7.2. Commercial
9.8. Market Size (US$ Mn) Forecast By Application, 2017-2027
9.8.1. Clinical
9.8.2. Commercial
9.9. Historical Market Size (US$ Mn) By Therapeutic Area, 2012-2016
9.9.1. Autoimmune Disease
9.9.2. Oncology
9.9.3. Metabolic Disease
9.9.4. Opthalmology
9.9.5. Cardiovascular Disease
9.9.6. Infectious Disease
9.9.7. Neurology
9.9.8. Respiratory Disorder
9.9.9. Others
9.10. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017-2027
9.10.1. Autoimmune Disease
9.10.2. Oncology
9.10.3. Metabolic Disease
9.10.4. Opthalmology
9.10.5. Cardiovascular Disease
9.10.6. Infectious Disease
9.10.7. Neurology
9.10.8. Respiratory Disorder
9.10.9. Others
9.11. Market Attractiveness Analysis
9.11.1. By Platform
9.11.2. By Product Type
9.11.3. By Application
9.11.4. By Therapeutic Area
9.12. Key Representative Market Participants
9.13. Market Presence (Intensity Map)

10. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027
10.1. Introduction
10.2. Regional Market Dynamics
10.2.1. Drivers
10.2.2. Restraints
10.2.3. Trends
10.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
10.3.1. GCC Countries
10.3.2. Turkey
10.3.3. North Africa
10.3.4. South Africa
10.3.5. Rest of MEA
10.4. Market Size (US$ Mn) Forecast By Country, 2017–2027
10.4.1. GCC Countries
10.4.2. Turkey
10.4.3. North Africa
10.4.4. South Africa
10.4.5. Rest of MEA
10.5. Historical Market Size (US$ Mn) By Platform, 2012-2016
10.5.1. Mammalian-based
10.5.2. Microbial-based
10.6. Market Size (US$ Mn) Forecast By Platform, 2017-2027
10.6.1. Mammalian-based
10.6.2. Microbial-based
10.7. Historical Market Size (US$ Mn) By Product Type, 2012-2016
10.7.1. Monoclonal Antibodies
10.7.2. Recombinant Proteins
10.7.3. Vaccines
10.7.4. Insulin
10.7.5. Interferons
10.7.6. Growth Factors
10.7.7. Others
10.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
10.8.1. Monoclonal Antibodies
10.8.2. Recombinant Proteins
10.8.3. Vaccines
10.8.4. Insulin
10.8.5. Interferons
10.8.6. Growth Factors
10.8.7. Others
10.9. Historical Market Size (US$ Mn) By Application, 2012-2016
10.9.1. Clinical
10.9.2. Commercial
10.10. Market Size (US$ Mn) Forecast By Application, 2017-2027
10.10.1. Clinical
10.10.2. Commercial
10.11. Historical Market Size (US$ Mn) By Therapeutic Area, 2012-2016
10.11.1. Autoimmune Disease
10.11.2. Oncology
10.11.3. Metabolic Disease
10.11.4. Opthalmology
10.11.5. Cardiovascular Disease
10.11.6. Infectious Disease
10.11.7. Neurology
10.11.8. Respiratory Disorder
10.11.9. Others
10.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017-2027
10.12.1. Autoimmune Disease
10.12.2. Oncology
10.12.3. Metabolic Disease
10.12.4. Opthalmology
10.12.5. Cardiovascular Disease
10.12.6. Infectious Disease
10.12.7. Neurology
10.12.8. Respiratory Disorder
10.12.9. Others
10.13. Market Attractiveness Analysis
10.13.1. By Country
10.13.2. By Platform
10.13.3. By Product Type
10.13.4. By Application
10.13.5. By Therapeutic Area
10.14. Key Representative Market Participants
10.15. Market Presence (Intensity Map)

11. Forecast Factors: Relevance and Impact

12. Forecast Assumptions

13. Competition Landscape
13.1. Competition Dashboard
13.2. Company Profiles (Details – Overview, Financials, Strategy, SWOT, Recent Developments)
13.2.1. Lonza Group AG
13.2.2. Baxter Biopharma Solutions
13.2.3. Samsung Biologics Co., Ltd.
13.2.4. Fujifilm Diosynth Biotechnologies
13.2.5. Boehringer Ingelheim GmbH
13.2.6. Patheon N.V.
13.2.7. Rentschler Biotechnologie GmbH
13.2.8. Biomeva GmbH
13.2.9. Probiogen AG
13.2.10. Cytovance Biologics, Inc.
13.2.11. KBI Biopharma, Inc.
13.2.12. WuXi Biologics
13.2.13. Abzena Plc
13.2.14. Vetter Pharma International GmbH
13.2.15. Sandoz International GmbH
13.2.16. Catalent, Inc.
13.2.17. AbbVie Contract Manufacturing (An AbbVie Company)
13.2.18. Ajinomoto Althea, Inc.

14. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027, By Region
14.1. Introduction/Key Findings
14.2. Historical Market Size (US$ Mn) Analysis By Region, 2012–2016
14.2.1. North America
14.2.2. Latin America
14.2.3. Western Europe
14.2.4. Eastern Europe
14.2.5. Asia Pacific excluding Japan
14.2.6. Japan
14.2.7. Middle East & Africa
14.3. Market Size (US$ Mn) Forecast By Region, 2017–2027
14.3.1. North America
14.3.2. Latin America
14.3.3. Western Europe
14.3.4. Eastern Europe
14.3.5. Asia Pacific excluding Japan
14.3.6. Japan
14.3.7. Middle East & Africa
14.4. Market Attractiveness Analysis By Region

15. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027, By Platform
15.1. Introduction/Key Findings
15.2. Historical Market Size (US$ Mn) Analysis By Platform, 2012–2016
15.2.1. Mammalian-based
15.2.2. Microbial-based
15.3. Market Size (US$ Mn) Forecast By Platform, 2017–2027
15.3.1. Mammalian-based
15.3.2. Microbial-based
15.4. Market Attractiveness Analysis By Platform

16. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027, By Product Type
16.1. Introduction/Key Findings
16.2. Historical Market Size (US$ Mn) Analysis By Product Type, 2012–2016
16.2.1. Monoclonal Antibodies
16.2.2. Recombinant Proteins
16.2.3. Vaccines
16.2.4. Insulin
16.2.5. Interferons
16.2.6. Growth Factors
16.2.7. Others
16.3. Market Size (US$ Mn) Forecast By Product Type, 2017–2027
16.3.1. Monoclonal Antibodies
16.3.2. Recombinant Proteins
16.3.3. Vaccines
16.3.4. Insulin
16.3.5. Interferons
16.3.6. Growth Factors
16.3.7. Others
16.4. Market Attractiveness Analysis By Product Type

17. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027, By Application
17.1. Introduction/Key Findings
17.2. Historical Market Size (US$ Mn) Analysis By Application, 2012–2016
17.2.1. Clinical
17.2.2. Commercial
17.3. Market Size (US$ Mn) Forecast By Application, 2017–2027
17.3.1. Clinical
17.3.2. Commercial
17.4. Market Attractiveness Analysis By Application

18. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area
18.1. Introduction/Key Findings
18.2. Historical Market Size (US$ Mn) Analysis By Therapeutic Area, 2012–2016
18.2.1. Autoimmune Disease
18.2.2. Oncology
18.2.3. Metabolic Disease
18.2.4. Opthalmology
18.2.5. Cardiovascular Disease
18.2.6. Infectious Disease
18.2.7. Neurology
18.2.8. Respiratory Disorder
18.2.9. Others
18.3. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017–2027
18.3.1. Autoimmune Disease
18.3.2. Oncology
18.3.3. Metabolic Disease
18.3.4. Opthalmology
18.3.5. Cardiovascular Disease
18.3.6. Infectious Disease
18.3.7. Neurology
18.3.8. Respiratory Disorder
18.3.9. Others
18.4. Market Attractiveness Analysis By Therapeutic Area

19. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027
19.1. Market Size and Y-o-Y Growth
19.2. Absolute $ Opportunity
19.3. Market Value Chain

Custom Market Research Services

MRRSE offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Get A Free Custom Research Quote